This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
Since the introduction of direct-acting antivirals, more patients with hepatitis C are achieving sustained virologic response than ever before. Even patients who failed previous interferon or DAA therapy have the opportunity for secondary treatment with newly developed drugs.
The following reports cover continued safety and efficacy analyses for new DAAs and continued studies on approved therapies, as well as data on SVR outcomes in specific demographics:
- Patients on opioid substitutes have better outcomes with interferon-free HCV regimens
- Viekirax safety, efficacy comparable in HCV with chronic kidney disease
- Mavyret effective for HCV genotypes 1, 4 in DAA-experienced patients
- Combined ruzasvir, uprifosbuvir shows suboptimal HCV pangenotypic efficacy
- Asian patients achieve SVR with ravidasvir, ritonavir, danoprevir, ribavirin combo
- Harvoni efficacy constant in HCV genotype 1 trials
- Combination sofosbuvir, ravidasvir effective in HCV genotype 4
- SVR in HCV genotype 1 improves insulin resistance
- 8-week Harvoni cost-effective alternative to 12-week regimen
- SVR after HCV treatment improves liver stiffness in progressive fibrosis